Get the Daily Brief
Latest Biotech News
Failed Phase 2 for Celldex’s prurigo nodularis antibody
Celldex Therapeutics said it will stop investigating its mast cell-targeting monoclonal antibody in prurigo nodularis after its Phase 2 study missed all efficacy measures. The setback sends a...
FDA decision timing for ivonescimab in HARMONi NSCLC
Summit Therapeutics released updated follow-up survival data for ivonescimab in a form of non-small cell lung cancer and outlined how outcomes may differ between Western and Asian patient groups....
Crystalys lands $130M Series B for late-stage gout drug
Crystalys Therapeutics raised an additional $130 million in a Series B round to advance its gout candidate dotinurad through Phase 3 and prepare for potential commercialization. The drug is...
Merger expansion for Tempus’ MRD footprint
Tempus AI agreed to buy Personalis for $1.5 billion, aiming to deepen its position in molecular residual disease testing. Personalis’ tumor-informed MRD approach complements Tempus’ tumor-naive...
Gene-therapy scale-up push with Broad, Boston Children’s, and Jackson Lab
The Broad Institute, Boston Children’s Hospital, and The Jackson Laboratory launched a new Center for Therapeutic Genetics aimed at standardizing how gene therapies are developed and delivered for...
$315M Series D to scale isotope supply and late-stage trials
Advancell raised an oversubscribed $315 million Series D round to accelerate its push to become a fully integrated global radiopharma developer. The funding supports late-stage clinical...
New CLIA-capable lab expansion for 10x Genomics in diagnostics
10x Genomics said it is expanding into clinical diagnostics by building a CLIA-certified laboratory expected to open next year within its headquarters campus in Pleasanton, California. The company...
M&A premium detail: Vertex the only bidder for Crinetics
Vertex Pharmaceuticals was the only bidder for Crinetics Pharmaceuticals in a contested process that still involved a substantial acquisition premium. The setup highlights how strategic assets in...
Gene-therapy delivery debate: in vivo CAR T takes center stage
Speakers at BIO Asia-Taiwan 2026 framed in vivo CAR T as a potential second phase of scalability for cell therapy, centering the discussion on delivery technologies. The session positioned in vivo...
Spatial proteomics collaboration for lung inflammation tests
BioAffinity Technologies partnered with Pictor to develop high-throughput sputum-based laboratory-developed tests for assessing lung inflammation in asthma and chronic obstructive pulmonary...
Biopharma M&A – Crinetics pursuit and deal premium dynamics
Vertex Pharmaceuticals moved to take control of Crinetics Pharmaceuticals amid a tight M&A field, positioning itself as the only bidder for Crinetics during a year highlighted by unusually large...
Oncology AI computing infrastructure – BMS expands Nvidia “AI factory”
Bristol Myers Squibb expanded its existing Nvidia partnership to build what it described as one of the most powerful AI supercomputers in biopharma, aimed at accelerating drug discovery. The...
Precision oncology diagnostics – Tempus to buy Personalis for $1.5B
Tempus AI agreed to acquire Personalis for $1.5 billion, expanding its molecular residual disease (MRD) testing platform. Under the deal terms, Personalis shareholders will receive $16.25 per...
Gene therapies for rare disease – Broad-led Center for Therapeutic Genetics gets $34.5M ARPA-H
The Broad Institute, Boston Children’s Hospital, and Jackson Laboratory launched a Center for Therapeutic Genetics to develop rare-disease gene therapies and establish standard protocols for...
Immuno-oncology diagnostics and spatial biology – 10x Genomics pushes CLIA lab build and Cleveland Clinic collaboration
10x Genomics advanced its clinical diagnostics expansion by planning a CLIA-certified laboratory set to open next year, building on its shift from primarily research tools to clinical...
Radiopharmaceuticals – Advancell raises oversubscribed $315M Series D for integrated isotope strategy
Advancell raised an oversubscribed $315 million Series D to accelerate its push to become a fully integrated global radiopharma developer. The financing is aimed at funding late-stage clinical...
Rare disease gene and cell therapy funding – Startup secures $310M via SPAC to commercialize colorectal cancer test
Freenome closed a $310 million SPAC merger with Perceptive Capital Solutions, starting trading on Nasdaq under ticker FRNM. The transaction includes a PIPE commitment led by Perceptive Advisors...
FDA diagnostics expansion – Seegene receives EUA for multiplex HSV/VZV/MPXV PCR
Seegene received Emergency Use Authorization from the US FDA for its Allplex HSV-1&2/VZV/MPXV multiplex real-time PCR assay. The test is intended to detect and differentiate herpes simplex virus...
Clinical development failure – Agios stops tebapivat in sickle cell disease after Phase 2 miss
Agios Pharmaceuticals ended further development of tebapivat, a next-generation oral pyruvate kinase activator in sickle cell disease, after disappointing Phase 2 results. The company said the...
Regulatory transparency – FDA CRL publication policy faces legal uncertainty
The FDA’s policy to increase transparency by publishing complete response letters (CRLs) has run into legal uncertainty, according to reporting that highlights shifting status around the...